- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 614383, 6 pages
Humoral Immune Response to Keyhole Limpet Haemocyanin, the Protein Carrier in Cancer Vaccines
1Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Aurora Hospital, Building 5, 3rd floor, P.O. Box 348, 00029 Helsinki, Finland
2Department of Bacteriology and Immunology, Haartman Institute, FIN-00014 University of Helsinki, Finland
3Departments of Microbiology and Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294-2170, USA
4Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 12853 Prague 2, Czech Republic
5The University of Alabama at Birmingham, Birmingham, AL 35294, USA
6Department of Medical Microbiology and Immunology, University of Turku, FIN-20520 Turku, Finland
Received 1 January 2011; Revised 16 March 2011; Accepted 30 March 2011
Academic Editor: Bernhard Moser
Copyright © 2011 A. Kantele et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. J. Pollard, K. P. Perrett, and P. C. Beverley, “Maintaining protection against invasive bacteria with protein- polysaccharide conjugate vaccines,” Nature Reviews Immunology, vol. 9, no. 3, pp. 213–220, 2009.
- S. F. Slovin, S. J. Keding, and G. Ragupathi, “Carbohydrate vaccines as immunotherapy for cancer,” Immunology and Cell Biology, vol. 83, no. 4, pp. 418–428, 2005.
- C. R. Flowers, “BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma,” Expert Review of Vaccines, vol. 6, no. 3, pp. 307–317, 2007.
- A. B. Heimberger and J. H. Sampson, “The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients,” Expert Opinion on Biological Therapy, vol. 9, no. 8, pp. 1087–1098, 2009.
- L. A. Holmberg and B. M. Sandmaier, “Vaccination with theratope (STn-KLH) as treatment for breast cancer,” Expert Review of Vaccines, vol. 3, no. 6, pp. 655–663, 2004.
- S. T. Lee, Y. F. Jiang, K. U. Park, A. F. Woo, and S. S. Neelapu, “BiovaxID: a personalized therapeutic cancer vaccine for non-hodgkin's lymphoma,” Expert Opinion on Biological Therapy, vol. 7, no. 1, pp. 113–122, 2007.
- S. S. Neelapu, S. T. Lee, H. Qin, S. C. Cha, A. F. Woo, and L. W. Kwak, “Therapeutic lymphoma vaccines: importance of T-cell immunity,” Expert Review of Vaccines, vol. 5, no. 3, pp. 381–394, 2006.
- C. Gatsogiannis and J. Markl, “Keyhole limpet hemocyanin: 9-Å CryoEM structure and molecular model of the KLH1 didecamer reveal the interfaces and intricate topology of the 160 functional units,” Journal of Molecular Biology, vol. 385, no. 3, pp. 963–983, 2009.
- J. R. Harris and J. Markl, “Keyhole limpet hemocyanin (KLH): a biomedical review,” Micron, vol. 30, no. 6, pp. 597–623, 1999.
- S. Husby, J. Mestecky, Z. Moldoveanu, S. Holland, and C. O. Elson, “Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding,” Journal of Immunology, vol. 152, no. 9, pp. 4663–4670, 1994.
- J. Mestecky, S. Husby, Z. Moldoveanu, F. B. Waldo, A. W. L. Van Den Wall Bake, and C. O. Elson, “Induction of tolerance in humans: effectiveness of oral and nasal immunization routes,” Annals of the New York Academy of Sciences, vol. 778, pp. 194–201, 1996.
- E. J. Kunkel and E. C. Butcher, “Plasma-cell homing,” Nature Reviews Immunology, vol. 3, no. 10, pp. 822–829, 2003.
- H. Sigmundsdottir and E. C. Butcher, “Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking,” Nature Immunology, vol. 9, no. 9, pp. 981–987, 2008.
- C. Berlin, E. L. Berg, M. J. Briskin et al., “α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1,” Cell, vol. 74, no. 1, pp. 185–195, 1993.
- D. Camerini, S. P. James, I. Stamenkovic, and B. Seed, “Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor,” Nature, vol. 342, no. 6245, pp. 78–82, 1989.
- T. K. Kishimoto, M. A. Jutila, and E. C. Butcher, “Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 6, pp. 2244–2248, 1990.
- L. J. Picker, T. K. Kishimoto, C. W. Smith, R. A. Warnock, and E. C. Butcher, “ELAM-1 is an adhesion molecule for skin-homing T cells,” Nature, vol. 349, no. 6312, pp. 796–799, 1991.
- E. L. Berg, T. Yoshino, L. S. Rott et al., “The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1,” Journal of Experimental Medicine, vol. 174, no. 6, pp. 1461–1466, 1991.
- A. Kantele, J. Zivny, M. Häkkinen, C. O. Elson, and J. Mestecky, “Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans,” Journal of Immunology, vol. 162, no. 9, pp. 5173–5177, 1999.
- A. Kantele, J. M. Kantele, E. Savilahti et al., “Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not patenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut,” Journal of Immunology, vol. 158, no. 2, pp. 574–579, 1997.
- A. Kantele, E. Savilahti, H. Tiimonen, K. Iikkanen, S. Autio, and J. M. Kantele, “Cutaneous lymphocyte antigen expression on human effector B cells depends on the site and on the nature of antigen encounter,” European Journal of Immunology, vol. 33, no. 12, pp. 3275–3283, 2003.
- J. M. Kantele, H. Arvilommi, S. Kontiainen et al., “Mucosally activated circulating human B cells in diarrhea express homing receptors directing them back to the gut,” Gastroenterology, vol. 110, no. 4, pp. 1061–1067, 1996.
- M. Quiding-Järbrink, I. Nordström, G. Granström et al., “Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses,” Journal of Clinical Investigation, vol. 99, no. 6, pp. 1281–1286, 1997.
- J. M. Kantele, A. Kantele, and H. Arvilommi, “Circulating immunoglobulin-secreting cells are heterogeneous in their expression of maturation markers and homing receptors,” Clinical and Experimental Immunology, vol. 104, no. 3, pp. 525–530, 1996.
- A. Kantele, “Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine,” Vaccine, vol. 8, no. 4, pp. 321–326, 1990.
- J. M. Kantele, E. Savilahti, M. Westerholm-Ormio et al., “Decreased numbers of circulating plasmablasts and differences in IgA1-plasmablast homing to skin in coeliac disease and dermatitis herpetiformis,” Clinical and Experimental Immunology, vol. 156, no. 3, pp. 535–541, 2009.
- S. H. Pakkanen, J. M. Kantele, Z. Moldoveanu et al., “Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids,” Clinical and Vaccine Immunology, vol. 17, no. 3, pp. 393–401, 2010.
- A. Kantele, H. Arvilommi, K. Iikkanen, et al., “Unique characteristics of intestinal immune system as inductor site after antigen re-encounter,” Journal of Infectious Diseases, vol. 191, no. 2, pp. 312–317, 2005.